Robeco Institutional Asset Management B.V. Raises Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

Robeco Institutional Asset Management B.V. raised its stake in shares of Royalty Pharma plc (NASDAQ:RPRX) by 8.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 548,761 shares of the biopharmaceutical company’s stock after purchasing an additional 43,926 shares during the quarter. Robeco Institutional Asset Management B.V. owned approximately 0.09% of Royalty Pharma worth $13,999,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in RPRX. Swedbank AB grew its position in shares of Royalty Pharma by 2.0% in the 3rd quarter. Swedbank AB now owns 11,027,370 shares of the biopharmaceutical company’s stock worth $311,964,000 after buying an additional 213,900 shares during the period. State Street Corp grew its position in shares of Royalty Pharma by 0.3% in the 3rd quarter. State Street Corp now owns 9,516,262 shares of the biopharmaceutical company’s stock worth $269,215,000 after buying an additional 29,451 shares during the period. Geode Capital Management LLC grew its position in shares of Royalty Pharma by 6.1% in the 3rd quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company’s stock worth $205,562,000 after buying an additional 417,490 shares during the period. Two Sigma Advisers LP grew its position in shares of Royalty Pharma by 44.7% in the 3rd quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock worth $85,809,000 after buying an additional 936,900 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Royalty Pharma by 58.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company’s stock worth $84,915,000 after buying an additional 1,103,341 shares during the period. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Price Performance

RPRX opened at $31.58 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.54. The stock has a market capitalization of $18.61 billion, a P/E ratio of 16.36 and a beta of 0.47. The company’s 50-day simple moving average is $27.23 and its two-hundred day simple moving average is $27.50. Royalty Pharma plc has a 52-week low of $24.05 and a 52-week high of $32.21.

Royalty Pharma Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be paid a dividend of $0.22 per share. The ex-dividend date of this dividend is Friday, February 21st. This represents a $0.88 annualized dividend and a yield of 2.79%. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio is currently 43.52%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on RPRX shares. TD Cowen raised shares of Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 5th. Finally, Citigroup dropped their price target on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research note on Friday, October 25th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $41.67.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.